News
November 18, 2019 | NBC News The National Institutes of Health in Bethesda, Maryland, is testing an experimental drug that could save lives in the fight against the opioid epidemic. October 17, 2019 | Amygdala Press Release ANS-6637 is a new chemical entity selective ALDH2 Inhibitor with a mechanism of action expected to prevent craving and relapse for patients being treated for substance use disorders including… March 28, 2019 | Amygdala Press Release March 21, 2019 | NIH Press Release A clinical trial of an experimental drug designed to treat cravings associated with opioid use disorder (OUD) has begun in the National Institutes of Health Clinical Center. September 19, 2018 | NIH/IHV Press Release February 16, 2017 | Amygdala Press Release
NIH Experiments With Drug to Reduce Opioid Cravings
Amygdala Neurosciences Announces Dosing of the First Patient in the NIH Funded Phase 2 Proof-Of-Concept study of ANS-6637 for the Treatment of Alcohol Use Disorder
Amygdala Neurosciences Announces Dosing the First Patients in the $12.4 Million NIH HEAL Initiative Funded SEARCH Program of Clinical Studies with ANS-6637
NIH to Test Experimental Drug to Curb Opioid Cravings
Institute of Human Virology (IHV) Awarded $12M to Combat Opioid Epidemic Through Clinical Research Trials
Amygdala Neurosciences Acquires GS-6637 from Gilead